Precipio, Inc. welcomed Christina Valauri to its board of directors effective January 1, 2024. Ms. Valauri is joining Precipio?s board to support management?s understanding of and interaction with the capital markets, as the company look towards 2024 to be an important period for the company from both a business growth, and financial perspective. Ms. Valauri brings a 30-year proven track record as a senior healthcare analyst and has held leadership roles that include US and Global Head of Equity Research and Managing Director at Cantor Fitzgerald, and senior equity research management roles at firms including ING, Credit Lyonnais (acquired by Credit Agricole), and Natixis.

She has been recognized by The Wall Street Journal?s ?Best on The Street? All-Star Analyst Survey and has received the Award for Excellence in Medical Education Public Affairs - Association of American Medical Colleges. Ms. Valauri is the founding partner and CEO of Sagestone Advisory, LLC.

Her background in equity securities research has provided a deep base of experience in pharmaceutical, biotech, and med-tech companies. She has extensive experience identifying and analyzing the commercial potential of breakthrough innovations, as well as mentoring and advising C-suite teams of private and public early-stage healthcare companies through product development, regulatory, go-to-market strategies, potential mergers and acquisitions, and IPOs. Ms. Valauri currently serves as an Entrepreneur In Residence at Weill Cornell Medicine BioVenture eLab where she applies her skills and experience in life sciences and business to support the organization?s mission to foster an entrepreneurial ecosystem related to the innovations of researchers, and clinicians.

Ms. Valauri earned her BA in Biology from Reed College and an MBA from Cornell University. After serving on Precipio?s board of directors for 6 years, Douglas Fisher, MD is stepping off the board to maintain a board of 7 directors and will remain as an observer moving forward.